Meridian Bioscience Restructures and Expands Life Sciences
By Biotechdaily staff writers Posted on 05 Apr 2007 |
Meridian Bioscience, Inc., (Cincinnati, Ohio, USA) announced that it has completed its restructuring and expansion of its former life science subsidiaries into one wholly-owned subsidiary, Meridian Life Science, Inc. (MLS).
Meridian Bioscience entered the life science arena primarily through its acquisitions of Biodesign International (a subsidiary of Gull Laboratories) in 1998, Viral Antigens, Inc. (VAI) in fiscal year 2000, and OEM Concepts, Inc. in January 2005. The former life science subsidiaries have now been combined and restructured as Meridian Life Science, Inc. and contain four life science brands. The restructuring was designed to combine the complementary strengths of each business, expand the global sales and marketing of all life science businesses as one company, and streamline the customer interactions.
Richard L. Eberly, President, Meridian Life Science, Inc., commented, "We are excited about the combination and expansion of Meridian Life Science, Inc. into a strategic business unit focused on becoming the world's leading supplier of biological materials used in applications to advance the diagnosis and treatment of diseases. Meridian Life Science will remain committed to utilizing its excellence in science to provide innovative solutions as a trusted partner in the manufacture and distribution of critical biologics. We will also continue to focus on building the broadest portfolio of biologics for life science industry and research.”
Meridian Life Science will continue its research, development, and manufacturing operations in Memphis, Tennessee; Saco, Maine; and Boca Raton, Florida. The MLS product brands have been structured to expand and align the sales and marketing capabilities to the medical diagnostic, biopharmaceutic, and life science research markets.
Biodesign International represents a product line of essential antigens, antibodies, and assay development reagents that are manufactured and distributed to diagnostic and pharmaceutical manufacturers as well as academic and life science researchers.
Viral Antigens represents a product line of viral proteins and critical assay reagents utilized by the major diagnostic manufacturers in the industry. Many of the viral proteins are custom-developed antigens that are used in infectious disease diagnostic assays such as rubella, hepatitis A, measles, mumps, Epstein-Barr virus, cytomegalovirus, toxoplasmosis, varicella zoster virus, HSV, and RSV. Several new viral antigens are in development for commercialization in 2007.
OEM Concepts serves as a large-volume producer of monoclonal antibodies that are critical components of commercial diagnostic products used in the diagnosis of infectious diseases and in the monitoring of human protein levels in metabolic disorders, pregnancy, and cardiac disease. OEM adds custom ascites manufacturing, in-vitro monoclonal production, and purification processing capabilities to Meridian's customer base of major diagnostic companies.
Meridian Biologics serves as an enabling technology provider for process development and pharmaceutical-grade manufacturing of biologicals used in new drugs and vaccines. Meridian's protein production facility is designed to support the manufacturing requirements for pre-clinical, Phase I, and Phase II clinical trials. Meridian is currently negotiating with several biopharmaceutical companies for the production of recombinant proteins for use in therapeutics and vaccines.
Related Links:
Meridian Bioscience
Meridian Bioscience entered the life science arena primarily through its acquisitions of Biodesign International (a subsidiary of Gull Laboratories) in 1998, Viral Antigens, Inc. (VAI) in fiscal year 2000, and OEM Concepts, Inc. in January 2005. The former life science subsidiaries have now been combined and restructured as Meridian Life Science, Inc. and contain four life science brands. The restructuring was designed to combine the complementary strengths of each business, expand the global sales and marketing of all life science businesses as one company, and streamline the customer interactions.
Richard L. Eberly, President, Meridian Life Science, Inc., commented, "We are excited about the combination and expansion of Meridian Life Science, Inc. into a strategic business unit focused on becoming the world's leading supplier of biological materials used in applications to advance the diagnosis and treatment of diseases. Meridian Life Science will remain committed to utilizing its excellence in science to provide innovative solutions as a trusted partner in the manufacture and distribution of critical biologics. We will also continue to focus on building the broadest portfolio of biologics for life science industry and research.”
Meridian Life Science will continue its research, development, and manufacturing operations in Memphis, Tennessee; Saco, Maine; and Boca Raton, Florida. The MLS product brands have been structured to expand and align the sales and marketing capabilities to the medical diagnostic, biopharmaceutic, and life science research markets.
Biodesign International represents a product line of essential antigens, antibodies, and assay development reagents that are manufactured and distributed to diagnostic and pharmaceutical manufacturers as well as academic and life science researchers.
Viral Antigens represents a product line of viral proteins and critical assay reagents utilized by the major diagnostic manufacturers in the industry. Many of the viral proteins are custom-developed antigens that are used in infectious disease diagnostic assays such as rubella, hepatitis A, measles, mumps, Epstein-Barr virus, cytomegalovirus, toxoplasmosis, varicella zoster virus, HSV, and RSV. Several new viral antigens are in development for commercialization in 2007.
OEM Concepts serves as a large-volume producer of monoclonal antibodies that are critical components of commercial diagnostic products used in the diagnosis of infectious diseases and in the monitoring of human protein levels in metabolic disorders, pregnancy, and cardiac disease. OEM adds custom ascites manufacturing, in-vitro monoclonal production, and purification processing capabilities to Meridian's customer base of major diagnostic companies.
Meridian Biologics serves as an enabling technology provider for process development and pharmaceutical-grade manufacturing of biologicals used in new drugs and vaccines. Meridian's protein production facility is designed to support the manufacturing requirements for pre-clinical, Phase I, and Phase II clinical trials. Meridian is currently negotiating with several biopharmaceutical companies for the production of recombinant proteins for use in therapeutics and vaccines.
Related Links:
Meridian Bioscience
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples
Channels
Clinical Chemistry
view channel
‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more
Low-Cost Portable Screening Test to Transform Kidney Disease Detection
Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more
New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read moreMolecular Diagnostics
view channel
New Genetic Tool Analyzes Umbilical Cord Blood to Predict Future Disease
Children are experiencing metabolic problems at increasingly younger ages, placing them at higher risk for serious health issues later in life. There is a growing need to identify this risk from birth... Read more
Spinal Fluid Biomarker for Parkinson’s Disease Offers Early and Accurate Diagnosis
Parkinson’s disease is a neurodegenerative condition typically diagnosed at an advanced stage based on clinical symptoms, primarily motor disorders. However, by this time, the brain has already undergone... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation
Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more
World’s First AI Model for Thyroid Cancer Diagnosis Achieves Over 90% Accuracy
Thyroid cancer is one of the most common cancers worldwide, and its precise management typically relies on two primary systems: (1) the 8th edition of the American Joint Committee on Cancer (AJCC) or ... Read more
Breakthrough Diagnostic Approach to Significantly Improve TB Detection
Tuberculosis (TB) remains the deadliest infectious disease globally, with 10.8 million new cases and 1.25 million deaths reported in 2023. Early detection through effective screening is crucial in identifying... Read more
Rapid, Ultra-Sensitive, PCR-Free Detection Method Makes Genetic Analysis More Accessible
Genetic testing has been an important method for detecting infectious diseases, diagnosing early-stage cancer, ensuring food safety, and analyzing environmental DNA. For a long time, polymerase chain reaction... Read moreTechnology
view channel
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more